查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134982

全球多重系統退化症症治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

Global Multiple System Atrophy Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

多重系統退化症症（MSA）是一種罕見的進行性神經退化性疾病，其特徵為自主神經功能障礙、類似帕金森氏症的症狀、小腦功能障礙和廣泛的神經功能衰退。儘管神經科學研究取得了顯著進展，但由於缺乏廣泛應用的疾病修正治療，MSA領域仍存在巨大的未滿足需求。目前的治療方法主要以緩解症狀為主，因此迫切需要能夠延緩或阻止疾病進展的創新療法。

對於尋求評估未來市場機會和競爭地位的製藥公司、生技公司、投資者、醫療顧問公司和研究機構而言，藥物研發管線分析的重要性日益凸顯。管線情報能夠提供關於臨床開發趨勢、治療標靶、分子類型、監管途徑、策略聯盟和商業化前景的洞察。隨著對疾病機制（尤其是α-突觸核蛋白聚集和神經退化）的科學認知不斷加深，處於不同臨床實驗階段的療法研發正在推動多重系統退化症症（MSA）研發管線的整體擴張。

市場促進因素

人們越來越重視疾病修正治療

  • 推動產業成長要素之一是治療方向從症狀治療轉向旨在改變潛在疾病進程的療法。研究人員正日益關注α-突觸核蛋白的累積、神經發炎、粒線體功能障礙和神經退化。
  • 對疾病修正治療的追求促使研究活動擴展到多種治療方法，從而創造了一個更具活力和競爭性的發展環境。

孤兒藥研發的擴展

  • 由於 MSA 在主要醫藥市場被歸類為罕見疾病，研發公司可以享受孤兒藥激勵措施，例如監管支持、市場獨佔權、降低費用和加速研發流程。
  • 這些激勵措施鼓勵生物技術和製藥公司進入該領域，從而有助於加強目前正在進行臨床實驗的療法的整體研發管線。

擴大臨床試驗活動

  • 隨著越來越多的公司將有前景的候選藥物推進到人體試驗階段，臨床開發活動也不斷擴大。早期和中期臨床計畫的重要性日益凸顯，因為申辦者需要評估藥物的安全性、有效性、生物標記以及疾病進展等終點指標。
  • 臨床試驗活動的擴展產生了寶貴的研發管線訊息，為整個MSA生態系統的策略投資決策提供了支持。

疾病生物學研究進展

  • 對多重系統退化症症（MSA）發病機制的深入了解正在加速新型治療標靶的發現。對α-突觸核蛋白病理、蛋白質聚集、神經保護路徑、發炎機制和基因調控的研究，為創新藥物的研發創造了新的機會。
  • 這些科學進步為更廣泛的研發計畫提供了支持，並增加了未來治療取得突破性進展的可能性。

市場限制因素

患者數量有限

  • 多重系統退化症症（MSA）是一種罕見疾病，全球患者人數相對較少。如此有限的患者群體給臨床試驗參與者的招募、流行病學調查的開展以及市場規模的估算都帶來了挑戰。
  • 招募受試者的困難可能會增加研發時間和成本，進而可能減緩研發進程。

臨床開發的高風險

  • 神經退化性疾病的藥物研發仍充滿巨大的科學不確定性和高失敗率。在多重系統退化症症（MSA）中，疾病進展的複雜性和變異性使得證明藥物具有顯著的臨床療效變得困難。
  • 許多有前景的療法在臨床評估過程中可能會遇到困難，這可能導致重大的投資風險。

缺乏檢驗的生物標記

  • 由於缺乏廣泛認可的生物標記或替代終點，評估治療效果變得極為困難。研發人員往往被迫依賴需要長期觀察的臨床結果指標。
  • 這些限制可能會增加開發的複雜性，並可能影響向監管機構提交申請的進度安排。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：多重系統退化症管路的動態變化

  • 促進因素
  • 約束條件
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Alterity Therapeutics
    • Biohaven
    • Lundbeck
    • Neurocrine Biosciences
    • AbbVie
  • 管線分析：依開發階段分類
    • 初始階段 I
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • MSA-P
    • MSA-C
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作機構分析
  • 近期和即將進行的管道活動
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Alterity Therapeutics
  • Biohaven
  • Lundbeck
  • Neurocrine Biosciences
  • AbbVie

第7章 圖表清單

第8章：圖表清單

第9章免責聲明

簡介目錄
Product Code: KSI-008829

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonian symptoms, cerebellar impairment, and widespread neurological deterioration. Despite significant advances in neuroscience research, MSA remains an area of substantial unmet medical need due to the absence of widely available disease-modifying treatments. Current therapeutic approaches are largely focused on symptomatic management, creating strong demand for innovative therapies capable of slowing or preventing disease progression.

Drug pipeline analysis has become increasingly important for pharmaceutical companies, biotechnology firms, investors, healthcare consultants, and research organizations seeking to evaluate future market opportunities and competitive positioning. Pipeline intelligence provides insights into clinical development trends, therapeutic targets, molecule types, regulatory pathways, strategic collaborations, and commercialization prospects. Growing scientific understanding of disease mechanisms, particularly alpha-synuclein aggregation and neurodegeneration, is supporting the development of a diverse range of investigational therapies and expanding the overall MSA pipeline landscape.

Market Drivers

Increasing Focus on Disease-Modifying Therapies

  • One of the primary growth drivers is the industry's transition from symptomatic treatment approaches toward therapies designed to modify the underlying disease process. Researchers are increasingly targeting alpha-synuclein accumulation, neuroinflammation, mitochondrial dysfunction, and neuronal degeneration.
  • The pursuit of disease-modifying interventions has expanded research activity across multiple therapeutic modalities, creating a more dynamic and competitive development environment.

Expansion of Orphan Drug Development

  • MSA qualifies as a rare disease in major pharmaceutical markets, allowing developers to benefit from orphan drug incentives such as regulatory support, market exclusivity, fee reductions, and accelerated development pathways.
  • These incentives are encouraging greater participation from biotechnology and pharmaceutical companies and are helping to strengthen the overall pipeline of investigational therapies.

Growing Clinical Trial Activity

  • Clinical development activity continues to increase as more companies advance promising candidates into human studies. Early-stage and mid-stage clinical programs are becoming increasingly important as sponsors evaluate safety, efficacy, biomarkers, and disease progression endpoints.
  • Growing clinical trial activity is generating valuable pipeline intelligence and supporting strategic investment decisions throughout the MSA ecosystem.

Advances in Disease Biology Research

  • Improved understanding of MSA pathogenesis has accelerated the identification of novel therapeutic targets. Research into alpha-synuclein pathology, protein aggregation, neuroprotective pathways, inflammatory mechanisms, and genetic regulation is creating new opportunities for innovative drug development.
  • These scientific advances are supporting a broader range of development programs and increasing the probability of future therapeutic breakthroughs.

Market Restraints

Limited Patient Population

  • As a rare disease, MSA affects a relatively small number of patients worldwide. The limited patient pool creates challenges for clinical trial recruitment, epidemiological studies, and commercial market sizing.
  • Recruitment difficulties may increase development timelines and costs, slowing pipeline progression.

High Clinical Development Risk

  • Neurodegenerative disease drug development remains associated with significant scientific uncertainty and elevated failure rates. Demonstrating meaningful clinical benefit in MSA can be challenging due to disease complexity and progression variability.
  • Many promising therapies may encounter difficulties during clinical evaluation, creating substantial investment risk.

Lack of Validated Biomarkers

  • The absence of widely accepted biomarkers and surrogate endpoints continues to complicate therapeutic assessment. Developers often rely on clinical outcome measures that require lengthy observation periods.
  • These limitations can increase development complexity and affect regulatory timelines.

Technology and Segment Insights

  • The global multiple system atrophy drug pipeline analysis market can be segmented by development stage, molecule type, mechanism of action, therapy platform, end user, and geography.
  • By development stage, the market includes discovery, preclinical, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and registration-stage programs. Discovery and preclinical programs account for a substantial share of pipeline activity as researchers continue identifying novel therapeutic targets. Phase II remains one of the most strategically significant segments because proof-of-concept data generated at this stage often influences future investment and partnership decisions.
  • By molecule type, the market includes small molecules, monoclonal antibodies, antisense oligonucleotides, gene therapies, cell therapies, peptides, and other advanced therapeutic modalities. Small molecules currently represent a significant portion of the pipeline due to established development pathways and scalable manufacturing. However, biologics, RNA-based therapies, and gene therapies are gaining momentum as developers pursue highly targeted treatment strategies.
  • By mechanism of action, the market includes alpha-synuclein targeting therapies, neuroprotective therapies, anti-inflammatory agents, protein aggregation inhibitors, gene-based approaches, cell-based therapies, and other emerging mechanisms. Alpha-synuclein-targeted therapies represent one of the most active development areas because protein aggregation is widely considered a central driver of disease progression.
  • By therapy platform, the market encompasses biologics, molecular therapeutics, RNA therapeutics, regenerative medicine, precision medicine approaches, and advanced neurological interventions. Emerging technologies are increasingly focused on addressing the root causes of disease rather than managing symptoms alone.
  • By end user, the market serves pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, investors, healthcare consulting firms, and competitive intelligence providers. Pharmaceutical and biotechnology companies account for a substantial share due to ongoing portfolio assessment and strategic planning activities.
  • Several notable investigational candidates are advancing through development, including Amlenetug, ATH434, AB-1005, Foralumab, KM-819, ION464, PMN442, and other emerging therapies targeting diverse disease pathways. The pipeline currently includes more than 20 companies and over 20 investigational products across multiple stages of development.
  • Technological innovation is playing an increasingly important role in pipeline development. Artificial intelligence, biomarker discovery platforms, advanced neuroimaging technologies, genomic research, and precision medicine tools are improving target identification, patient stratification, and clinical trial design. These capabilities are enhancing development efficiency and supporting more sophisticated therapeutic approaches.
  • Geographically, North America represents the leading market due to strong neuroscience research infrastructure, significant rare disease funding, active clinical development programs, and favorable orphan drug policies. Europe remains an important market supported by collaborative research initiatives and regulatory incentives. Asia-Pacific is expected to experience growing activity as healthcare investments increase and neurological research capabilities expand.

Competitive and Strategic Outlook

  • The competitive landscape is becoming increasingly dynamic as biotechnology firms and pharmaceutical companies pursue differentiated strategies for disease modification. Companies are investing heavily in alpha-synuclein-targeting therapies, neuroprotective agents, antisense technologies, gene therapies, and regenerative medicine approaches.
  • Strategic partnerships, licensing agreements, research collaborations, and co-development arrangements are becoming common as organizations seek to combine scientific expertise, clinical capabilities, and financial resources. Biotechnology companies continue to drive much of the innovation, while larger pharmaceutical organizations are increasingly participating through acquisitions, partnerships, and targeted investments.
  • Leading organizations active within the pipeline include companies such as Alterity Therapeutics, Biohaven, Lundbeck, AbbVie, Neurocrine Biosciences, Ionis Pharmaceuticals, AskBio, Ono Pharmaceutical, ProMIS Neurosciences, and several emerging biotechnology developers. Their collective efforts are expanding therapeutic diversity and strengthening the long-term outlook for MSA treatment innovation.

Conclusion

  • The global multiple system atrophy drug pipeline analysis market is poised for significant expansion through 2031, supported by increasing rare disease research, growing orphan drug incentives, advances in disease biology, and expanding clinical development activity. The pipeline is evolving toward mechanism-based therapies that target alpha-synuclein pathology, neurodegeneration, and disease progression. While challenges related to patient recruitment, biomarker development, and clinical risk remain, ongoing innovation across small molecules, biologics, antisense therapies, gene therapies, and regenerative medicine platforms is expected to create substantial opportunities for stakeholders throughout the MSA therapeutic ecosystem.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. MULTIPLE SYSTEM ATROPHY PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Alterity Therapeutics
    • 5.1.2. Biohaven
    • 5.1.3. Lundbeck
    • 5.1.4. Neurocrine Biosciences
    • 5.1.5. AbbVie
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. MSA-P
    • 5.4.2. MSA-C
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Alterity Therapeutics
  • 6.2. Biohaven
  • 6.3. Lundbeck
  • 6.4. Neurocrine Biosciences
  • 6.5. AbbVie

7. LIST OF TABLES

8. LIST OF FIGURES

9. DISCLAIMER